Seoul-based Genuv is developing a competitor to Roche’s anti-PD-1:IL-2 fusion for solid tumors; advancing a MEK inhibitor for neurodegeneration
BY DANIELLE GOLOVIN, BIOPHARMA ANALYST
Sungho Han, a rare female South Korean CEO, founded Genuv in 2016 with two goals: to engineer antibodies for cancer that reduce systemic toxicity and to find neuroprotective small molecules for neurodegenerative diseases.
Genuv Inc. has three antibody platforms, dubbed Shine Mouse, NuvoFc and NuvoMab, each of which is designed to generate antibodies that can recognize more diverse epitopes than conventional methods...
To view original article, please click here.